Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

+ DOXIL to VELCADE monotherapy, the standard of care in patients with previously treated MM. Results were presented by Dr. Harousseau and showed:

    -- A survival advantage was observed for the VELCADE + DOXIL combination,

       after approximately 20 percent of events occurred (p<0.05, hazard

       ratio=1.406, 95 percent confidence interval [1.002; 1.972])

    -- Median time to progression (TTP) of 9.3 months for the combination, a

       43 percent, highly statistically significant reduction in risk of

       disease progression over the control arm (p<0.00001)

    -- A predictable safety profile consistent with the known toxicities of

       the two agents, including thrombocytopenia, neutropenia and anemia

The trial included 646 patients who had received at least one prior therapy. Patients were randomized in a one-to-one ratio, with 322 patients receiving VELCADE at 1.3 mg/m2 on days 1, 4, 8 and 11 of the 21-day cycle and 324 patients receiving the same dose and schedule of VELCADE with the addition of DOXIL at 30 mg/m2 given on day 4 of each cycle. Patients were treated for up to eight cycles. The primary endpoint of the study was TTP as defined by the interval between the date of randomization and the date of disease progression, including relapse after complete response or death due to disease progression. In both arms, 66 percent of patients had received more than two prior therapies before entering the trial. Responses were assessed by European Group for Blood and Marrow Transplantation (EBMT) criteria.

About Multiple Myeloma (MM)

Multiple myeloma is the second most common hematologic malignancy and although the disease is predominantly a cancer of the elderly (the average age of onset is 65 to 70 years of age), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approxi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

Post Your Comments:
(Date:11/27/2009)...LTLAKECITY,Nov.27/PRNewswire-FirstCall/--Booth-364...,apremiersupplierofX-raytubesandflatpaneldigitalim...heRSNAAnnualMeetinginChicago,Ill.fromNovember29-De...chnologyformultiplemodalitiesaswellasspecializedca...llshowcasethelatestX-raytechnologyincluding: ,,...
(Date:11/25/2009)...NOGAPARK,Calif.,Nov.25/PRNewswire/--PraxisElectron...ricanAcademyofFamilyPhysicians,(AAFP)FamilyPractic...provingmedicalquality,healthmaintenance,anddisease...n.Praxisalsoranked#1amongdoctorsindicatingtheirEMR...,Praxisalsorankednumberoneinthecountryinprovidinge...
(Date:11/25/2009)...INCETON,N.J.,Nov.25/PRNewswire-FirstCall/--Pharmas...alcompanycommittedtodiscovering,developingandcomme...dfinancialresultsforthefiscalyearendedSeptember30,...ncash,cashequivalentsandshortterminvestments. ,... ,, Phase2bTrial ,, InlateNovember2009,a...
Breaking Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Scientists Spot Clue to Cancers Aggressiveness 56441 1Lapatinib shows minimal effect against liver cancer 56439 1Lapatinib shows minimal effect against liver cancer 56439 2Lapatinib shows minimal effect against liver cancer 56439 3Team reveals molecular mechanism underlying a form of diabetes 56437 1Team reveals molecular mechanism underlying a form of diabetes 56437 2
...armaceuticals, a privately-held biopharmaceutical ...ollment in the Company,s second pivotal Phase 3 cl... Together with the previously completed first pivo... fully enrolled its planned pivotal Phase 3 studie...e oral therapy currently in development for the tr...
...ut tumor growth and reduced the risk of disease pr... , - Only once-daily oral cancer treatment to dire...ontrols tumor cell division and blood vessel growt...ntial of Afinitor in multiple additional cancers ,...ed today that Afinitor(R) (everolimus) tablets has...
Other Medicine Technology:QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 3Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 2Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 3Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 4Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 5Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 6Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 7Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib 8
(Date:11/27/2009)...UILLY-SUR-SEINE,France,Nov.27/PRNewswire/--TeamGar...teamdedicatedtoethicalsportinganddevelopingthenext...illbecomeTeamGarmin-TransitionswiththeadditionofTr...Opticalistheworld,sleadingmanufacturerofadaptiveey...yinthewidestselectionofspectaclelensessuchasTransi...
(Date:11/27/2009)...tes to bring unprecedented medical, economic burde...HealthDay News) -- The number of people with diabe...r the next 25 years, a new study predicts. , Th...lion people with the disease, up from 23.7 million...ng people with diabetes will triple, the study als...
(Date:11/27/2009)... Specialist manufacturers who use m...re saving millions of dollars by bringing in techn... Increasing numbers of pro-active medical manufact...the concept stage of their projects, ensuring that...gn processes or potentially outdated technology. ...
(Date:11/26/2009)...ext 25 years, the number of Americans living with ...million in 2009 to 44.1 million in 2034. Over the ...le, rising from $113 billion to $336 billion, even...searchers based at the University of Chicago repor...e number of those with diabetes covered by Medicar...
(Date:11/26/2009)... No more letters from the North Pol...ized text messages from Santa , ...ncrease operational efficiencies at the North Pole...keep children all over the globe informed of his C...Santa’s research department have identified ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
... NCCN names Cold Spring Publishing, LLC, as the ne...e National Comprehensive Cancer Network. Cold Spri... company led by Jack Gentile, founder of PRR, Inc....y(TM). , , FORT WASHINGTON, Pa., Feb. 10 JNCCN ...
...China, Feb. 10 /PRNewswire-Asia-FirstCall/ -- Chin...r ,the Company,) (Nasdaq: CSKI ), a,leading full...-the-counter,drugs in the People,s Republic of Chi...ibution from its recent,acquisitions, the Company ...
...led 2.7 million prescriptions through AZ&Me(TM...el., Feb. 10 AstraZeneca (NYSE: AZN ) announc...s to 440,541 patients in the United States last ye...neca is committed to helping patients who are faci...
...b. 10 HMS (Nasdaq: HMSY ) today announced that ...m Neighborhood Health Providers and Optima Health,... lives to its managed care portfolio. HMS will pro...coverage not previously known for its Medicaid mem...
...ems to reduce the risk of cognitive impairment, de...s) -- Chalk up another endorsement for the so-call...s rich in fruits, vegetables, fish and olive oil, ... -- marked by forgetfulness and difficulty concent...
...Calif., Feb. 10 Firefighter and wife help others ... Veteran firefighter Bryan Russell, from the "OC,"...nnifer found the hero in her life when she met fir...e asks, "Do you know any single people?" In Jenn a...
Other Medicine News:Health News:JNCCN Names New Publishing Company 2Health News:JNCCN Names New Publishing Company 3Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 2Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 3Health News:AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008 2Health News:HMS Awarded New Contracts for Managed Care Services 2Health News:Mediterranean Diet Aids the Aging Brain: Study 2Health News:Mediterranean Diet Aids the Aging Brain: Study 3Health News:Heroes Find Love, Love Finds Heroes 2
Urocare® Latex Urinary Leg Bag - Short-Wide
Urocare® Latex Urinary Leg Bag - Large
Medtronic Resting Heart™ System
DLP Recirculation Adapter, Y-Type
Medicine Products: